Skip to content
Study details
Enrolling now

Estrogen Supplementation and Bone Health in Women With CF

Johns Hopkins University
NCT IDNCT05704036ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

75

Study length

about 3.8 years

Ages

0–100

Sex

Female only

Locations

1 site in MD

About this study

Researchers are testing whether estrogen supplementation, including transdermal estrogen patches, affects bone health in women with cystic fibrosis. The trial also explores the feasibility of using transdermal estrogen and compares different forms of hormonal contraception on bone health. Participants will have their hormone levels, bone density, and quality of life assessed over time.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Progesterone
  • 2.Take Transdermal estrogen
PhasePhase 4
DrugProgesterone
Routeoral

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low7%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

progesterone (Progestin hormone; prepares uterus lining), Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers) (Estrogen Receptor Agonists)

Drug routes

oral (Oral Capsule), transdermal

Endpoints

Secondary: Change in quality of life as assessed by Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score (CFRSD-CRISS) questionnaire

Body systems

Respiratory